ARCHIVES

DCT Board Okays Concepts Of Four New Grant Projects, Four Competitive Contract Delays Chlordane Study

This article is from The Cancer Letter archive.

Vol. 10 No. 10 | March 9, 1984

Download PDF Visit The Full Archive

Related Articles

FDA Ceases Exclusion Of Women From Early Drug Studies

May 7, 1993

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

August 15, 1997

In Brief: Fabien Calvo named chief scientific officer of Cancer Core Europe

December 19, 2014

ODAC Advises Approval Of Tamoxifen For Male Breast Cancer Treatment

November 27, 1992

Men With PSA Of 7 Or Higher More Likely To Have Biopsy

February 25, 2005

Academic Oncologists Reluctant To Give ESAs In Adjuvant Breast Cancer Setting.

December 7, 2007